Short delay of the antibiotic resistance data

Scandion Oncology A/S (“Scandion Oncology”) hereby announces that the company has been informed by the State Serum Institute in Copenhagen that conducts the animal experiments with the antibiotic-resistant bacteria and the Scandion Oncology compounds, that due to the coronavirus, the State Serum Institute must postpone the last of three animal studies until the coronavirus situation is under control. Scandion Oncology estimates that the final data will be published during April-May 2020 instead of March 2020.

The State Serum Institute (SSI) in Copenhagen is the service provider of Scandion Oncology’s animal experiments with the antibiotic-resistant bacteria and the Scandion Oncology compounds. SSI has informed Scandion Oncology, that due to the coronavirus, the last of three animal studies is postponed until the coronavirus is under control. Scandion Oncology estimates that the final data will be published during April-May 2020 instead of March 2020. It should be mentioned that SSI together with the Danish Health Authority are the Danish Institutions being involved in testing for coronavirus and for validating new corona medicine.

 

In 2019 Scandion Oncology announced positive preclinical results in antibiotic resistance. Scandion Oncology discovered that a number of the company's compounds are able to overcome antibiotic resistance in bacterial infections through a different mechanism of action than the one related to reversing cancer resistance. Scandion Oncology has worked on extending the company's insight and understanding of this interesting effect. During the process, Scandion Oncology has identified analogues with more than tenfold higher activity than the original compound and generated very interesting data on the mode of action of these compounds. In parallel to these activities, Scandion Oncology wanted to test the anti-microbial effects in animal models of serious human antibiotic-resistant bacterial infections.

 

CEO Nils Brünner comments

“It is important to state that we all have to accept that the world has changed over the last weeks and especially people being involved in the fight against corona have to focus on this work. Due to the situation, there will be a short delay in the announcement of our results from the animal testing in antibiotic-resistant bacteria and we expect to publish the results in April-May instead of March. It should be emphasized that we are only lacking the last of three animal experiments.”

 

For further information regarding Scandion Oncology, please contact:

Nils Brünner, CEO

Phone: +45 26 14 47 08

E-mail: nb@scandiononcology.com

 

This information is information that Scandion Oncology is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on March 20, 2020.

 

Scandion Oncology A/S is a biotechnology company that addresses and tackles one of the greatest challenges in modern oncology - the effective treatment of cancer which contains chemotherapy-resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company's leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. In addition to SCO-101 the Company has two other drug candidates, SCO-201 and SCO-301. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018.

About Us

Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing one of the most important challenges in modern oncology – the effective treatment of cancer which contains drug resistant cell clones or which has developed resistance to a previously prescribed cancer drug. The Company’s leading candidate drug, SCO-101, is now ready for phase II testing in patients with drug resistant cancer disease.

Subscribe